CURRENT RESEARCH IN TRANSLATIONAL MEDICINE 是一份同行评审期刊，出版全球血液学、免疫学、感染学、造血细胞移植以及细胞和基因治疗领域的临床和基础研究。该杂志考虑出版英文社论、原创文章、评论和简短报告，包括案例报告。投稿旨在引起人们对实验医学和转化研究的关注。 CURRENT RESEARCH IN TRANSLATIONAL MEDICINE 定期出版专题，并在所有主要国际数据库中被索引（2017 年影响因子为 1.9）。 CURRENT RESEARCH IN TRANSLATIONAL MEDICINE 涵盖的核心领域是：血液学、免疫学、感染学、造血学、细胞移植、细胞和基因治疗。

Current Research in Translational Medicine is a peer-reviewed journal that publishes clinical and basic research in the fields of hematology, immunology, infectious diseases, hematopoietic cell transplantation, and cell and gene therapy on a global scale. The journal considers submissions of English editorials, original articles, reviews, and short reports, including case reports, aimed at raising awareness of experimental medicine and translational research. Current Research in Translational Medicine regularly publishes special issues and is indexed in all major international databases (with an impact factor of 1.9 in 2017). The core areas covered by the journal include hematology, immunology, infectious diseases, hematopoiesis, cell transplantation, and cell and gene therapy.

《Current Research in Translational Medicine》是一份经过同行评审的期刊，专注于全球范围内的血液学、免疫学、感染学、造血细胞移植以及细胞和基因治疗领域的临床和基础研究。该期刊欢迎英文社论、原创研究文章、评论和简短报告的投稿，包括案例报告，旨在引起对实验医学和转化研究的关注。《Current Research in Translational Medicine》定期出版专题，并在所有主要国际数据库中被索引（2017年影响因子为1.9）。该期刊涵盖的核心领域包括：血液学、免疫学、感染学、造血学、细胞移植以及细胞和基因治疗。

Current Research in Translational Medicine

Human mesenchymal stem cells (hMSCs) are multipotent cells and an attractive therapeutic agent in regenerative medicine and intensive clinical research. Despite the great potential, the limitation that needs to be overcome is the necessity of ex vivo expansion because of insufficient number of hMSCs presented within adult organs and the high doses required for a transplantation. As a result, numerous research studies aim to provide novel expansion methods in order to achieve appropriate numbers of cells with preserved therapeutic quality. Bioreactor-based cell expansion provide high-level production of hMSCs in accordance with good manufacturing practice (GMP) and quality standards. This review summarizes current knowledge about the hMSCs manufacturing platforms with a main focus to the application of bioreactors for large-scale production of GMP-grade hMSCs.

Marina Gazdic Jankovic

Miodrag Stojkovic

Sanja Bojic

Nemanja Jovicic

Marina Miletic Kovacevic

Zeljko Ivosevic

Aleksandar Juskovic

Vojin Kovacevic

Biljana Ljujic

Current research in translational medicine

Curr Res Transl Med

Scaling up human mesenchymal stem cell manufacturing using bioreactors for clinical uses.

利用生物反应器扩大人骨髓间充质干细胞生产规模以供临床使用

In recent years, chimeric antigen receptor (CAR) T-cell therapy has emerged as a groundbreaking approach in cancer immunotherapy. Particularly in hematologic malignancies, such as B-cell acute lymphoblastic leukemia (B-ALL), B cell lymphomas and multiple myeloma. CAR-T therapy has demonstrated remarkable clinical efficacy, leading to the approval of several CAR-T cell products and offering significant benefits to numerous leukemia patients. Despite these successes, the application of CAR-T cells in solid tumors remains limited due to significant challenges, including immunosuppressive tumor microenvironments, heterogeneous antigen expression, and treatment-associated toxicities. In parallel with CAR-T development, researchers are investigating other immune cell platforms to overcome these obstacles. Among these, invariant natural killer T (iNKT) cells have garnered increasing attention for their unique immunological properties. Unlike conventional T cells, iNKT cells are a subset of T lymphocytes characterized by the expression of a semi-invariant T-cell receptor (TCR) that recognizes lipid antigens presented by CD1d molecules. This distinctive antigen recognition mechanism enables iNKT cells to bridge innate and adaptive immunity, granting them potent antitumor activity and the ability to modulate the tumor microenvironment. Additionally, iNKT cells exhibit intrinsic resistance to exhaustion and an enhanced ability to infiltrate solid tumors compared to traditional T cells. Building on these properties, researchers are leveraging CAR technology to enhance iNKT cell tumor-targeting capabilities, aiming to overcome barriers encountered in solid tumor therapy. This review provides an in-depth discussion of the application and therapeutic potential of CAR-iNKT cells in cancer immunotherapy, with a focus on their advantages over conventional CAR-T cells and their role in addressing the challenges of solid tumor treatment.

Zixuan Wang

Guangji Zhang

CAR-iNKT cell therapy: mechanisms, advantages, and challenges.

CAR-iNKT细胞疗法：机制、优势与挑战

Moloud Ahmadi

Nicholas Putnam

Max Dotson

Danny Hayoun

Jasmine Padilla

Nujhat Fatima

Prajakta Bhanap

Gertrude Nonterah

Xavier de Mollerat du Jeu

Yongchang Ji

Accelerating CAR T cell manufacturing with an automated next-day process

加速CAR T细胞制造的自动化次日工艺

Tamim Alsuliman

Paolo Musiu

Lugien AlAsadi

Ziad Aljarad

Zora Marjanovic

Amer Beitinjaneh

Réda Garidi

Sexual and emotional life among patients with hematological malignancy - special concerns in low- and middle- income countries (LMICs)

血液系统恶性肿瘤患者的性及情感生活——低收入和中等收入国家（LMICs）的特殊关注

Thibaud Loupret

Laurie De Coster

Camille Lemaçon

Emma Gadon

Philippe Bertin

Pascale Vergne-Salle

Non-hematological triggers of VEXAS syndrome: A case report and literature review.

非血液学触发因素导致的VEXAS综合征：病例报告与文献综述。

Abdullah Sezer

Öznur Kaya Güneş

Burçak Kurucu

DNMT3A-related overgrowth syndrome presenting with immune thrombocytopenic purpura

DNMT3A相关过度生长综合征伴免疫性血小板减少性紫癜

Abbreviation	Curr. Res. Transl. Med.
Journal Impact	3.07
Quartiles(Global)	MEDICINE, RESEARCH & EXPERIMENTAL(Q2)

ISSN	2452-3186
h-index	67

Publication Information	Publisher: Elsevier Masson s.r.l.，Publishing cycle: ，Journal Type: journal，Open Access Journals: No
Basic data	Year of publication: 2016，Proportion of original research papers: 85.71%，Self Citation Rate:6.20%， Gold OA Rate: 20.93%

Current Research in Translational Medicine

Journal Citation Format

A journal article with 1 author

A journal article with 2 authors

A journal article with 3 authors

A journal article with 5 or more authors

Books Citation Format

Thesis Citation Format

Web sites Citation Format

Patent Citation Format

Staying up late manually editing references? ivySCI automatically matches journals and helps you generate references with a single click.

Share Submission Experience

Scaling up human mesenchymal stem cell manufacturing using bioreactors for clinical uses.

CAR-iNKT cell therapy: mechanisms, advantages, and challenges.

Accelerating CAR T cell manufacturing with an automated next-day process

Sexual and emotional life among patients with hematological malignancy - special concerns in low- and middle- income countries (LMICs)

Non-hematological triggers of VEXAS syndrome: A case report and literature review.

CAR-iNKT cell therapy: mechanisms, advantages, and challenges.

Accelerating CAR T cell manufacturing with an automated next-day process

Sexual and emotional life among patients with hematological malignancy - special concerns in low- and middle- income countries (LMICs)

Non-hematological triggers of VEXAS syndrome: A case report and literature review.

DNMT3A-related overgrowth syndrome presenting with immune thrombocytopenic purpura